Patents by Inventor Jayakanth Kankanala

Jayakanth Kankanala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS
    Publication number: 20260116890
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Application
    Filed: June 4, 2025
    Publication date: April 30, 2026
    Inventors: David HUNG, Jayakanth KANKANALA, Christopher Paul MILLER, Jeremy David PETTIGREW, Son Minh PHAM, Ihab S. DARWISH
  • HETEROCYCLIC COMPOUNDS AS BET INHIBITORS
    Publication number: 20250276978
    Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.
    Type: Application
    Filed: October 14, 2024
    Publication date: September 4, 2025
    Inventors: Son Minh PHAM, Sarvajit CHAKRAVARTY, Jayakanth KANKANALA, Jiyun CHEN, Chris P. MILLER, Jeremy D. PETTIGREW, Anjan Kumar NAYAK, Anup BARDE
  • Anti-cancer nuclear hormone receptor-targeting compounds
    Patent number: 12398121
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: November 22, 2022
    Date of Patent: August 26, 2025
    Assignee: NUVATION BIO INC.
    Inventors: David Hung, Son Minh Pham, Sarvajit Chakravarty, Jiyun Chen, Jayakanth Kankanala, Anup Barde, Anjan Kumar Nayak
  • Anti-cancer nuclear hormone receptor-targeting compounds
    Patent number: 12208141
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: September 22, 2023
    Date of Patent: January 28, 2025
    Assignee: NUVATION BIO INC.
    Inventors: David Hung, Son Minh Pham, Sarvajit Chakravarty, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anup Barde, Anjan Kumar Nayak
  • ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS
    Publication number: 20240352027
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Application
    Filed: October 10, 2023
    Publication date: October 24, 2024
    Inventors: David HUNG, Jayakanth KANKANALA, Christopher Paul MILLER, Jeremy David PETTIGREW, Son Minh PHAM, Ihab S. DARWISH
  • HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20240343710
    Abstract: The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating PARP1 activity and may be used in the treatment of disorders in which PARP1 activity is implicated, such as cancer.
    Type: Application
    Filed: February 21, 2024
    Publication date: October 17, 2024
    Inventors: Jayakanth KANKANALA, Jeremy D. PETTIGREW, Son Minh PHAM
  • Anti-cancer nuclear hormone receptor-targeting compounds
    Patent number: 12006314
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, such as a compound of Formula I: or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: June 11, 2024
    Assignee: NUVATION BIO INC.
    Inventors: David Hung, Jayakanth Kankanala, Christopher Paul Miller, Jeremy David Pettigrew, Son Minh Pham, Ihab S. Darwish
  • ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS
    Publication number: 20240181066
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Application
    Filed: September 22, 2023
    Publication date: June 6, 2024
    Inventors: David HUNG, Son Minh PHAM, Sarvajit CHAKRAVARTY, Jiyun CHEN, Jayakanth KANKANALA, Jeremy D. PETTIGREW, Anup BARDE, Anjan Kumar NAYAK
  • HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20240132522
    Abstract: The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating PARP1 activity and may be used in the treatment of disorders in which PARP1 activity is implicated, such as cancer.
    Type: Application
    Filed: August 29, 2023
    Publication date: April 25, 2024
    Inventors: Jayakanth KANKANALA, Jeremy D. PETTIGREW, Aurelia CONTE, Jiyun CHEN, Son Minh PHAM
  • HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20240132449
    Abstract: The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating PARP1 activity and may be used in the treatment of disorders in which PARP1 activity is implicated, such as cancer.
    Type: Application
    Filed: August 29, 2023
    Publication date: April 25, 2024
    Inventors: Jayakanth KANKANALA, Jeremy D. PETTIGREW, Jiyun CHEN, Son Minh PHAM
  • Anti-cancer nuclear hormone receptor-targeting compounds
    Patent number: 11952349
    Abstract: The disclosure relates to anti-cancer compounds derived from a payload which binds to poly(ADP-ribose) polymerase (PARP) and a nuclear steroid-targeting epitope (B of Formula I), which components are covalently linked via a linker, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: April 9, 2024
    Assignee: Nuvation Bio Inc.
    Inventors: Son Minh Pham, Jayakanth Kankanala, Jeremy Pettigrew, Christopher Paul Miller
  • Anti-cancer nuclear hormone receptor-targeting compounds
    Patent number: 11834458
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: December 5, 2023
    Assignee: NUVATION BIO INC.
    Inventors: David Hung, Jayakanth Kankanala, Christopher Paul Miller, Jeremy David Pettigrew, Son Minh Pham, Ihab S. Darwish
  • Anti-cancer nuclear hormone receptor-targeting compounds
    Patent number: 11826430
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: November 28, 2023
    Assignee: NUVATION BIO INC.
    Inventors: David Hung, Son Minh Pham, Sarvajit Chakravarty, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anup Barde, Anjan Kumar Nayak
  • HETEROCYCLIC COMPOUNDS AS BET INHIBITORS
    Publication number: 20230174545
    Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.
    Type: Application
    Filed: April 28, 2021
    Publication date: June 8, 2023
    Inventors: Son Minh PHAM, Jayakanth KANKANALA, Chris P. MILLER, Jeremy D. PETTIGREW
  • ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS
    Publication number: 20230122310
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Application
    Filed: November 22, 2022
    Publication date: April 20, 2023
    Inventors: David Hung, Son Minh Pham, Sarvajit Chakravarty, Jiyun Chen, Jayakanth Kankanala, Anup Barde, Anjan Kumar Nayak
  • SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORS
    Publication number: 20230118115
    Abstract: This invention provides for substituted pyrazolo[3,4-d]pyrimidine compounds of the Formula (I): as Wee1 inhibitors. The substituted pyrazolo[3,4-d]pyrimidine compounds may find use as therapeutic agents for the treatment of diseases. The substituted pyrazolo[3,4-d]pyrimidine compounds may also find particular use in oncology.
    Type: Application
    Filed: May 12, 2022
    Publication date: April 20, 2023
    Inventors: Sarvajit CHAKRAVARTY, Son Minh PHAM, Jayakanth KANKANALA, Brahmam PUJALA, Sanjeev SONI, Puja JAISWAL, Deepak PALVE, Varun KUMAR
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20230109104
    Abstract: Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: April 8, 2022
    Publication date: April 6, 2023
    Inventors: Sarvajit CHAKRAVARTY, Son Minh PHAM, Jayakanth KANKANALA, Anil Kumar AGARWAL, Brahmam PUJALA, Sanjeev SONI, Satish K. ARYA, Deepak PALVE, Ashu GUPTA, Varun KUMAR
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20230062022
    Abstract: Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: October 1, 2021
    Publication date: March 2, 2023
    Inventors: Son Minh PHAM, Sarvajit Chakravarty, Jayakanth Kankanala, Brahmam Pujala, Amit Shete, Bhawana Bhatt, Anil Kumar Agarwal, Sanjeev Soni, Jiyun Chen
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230066315
    Abstract: Compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Application
    Filed: January 17, 2020
    Publication date: March 2, 2023
    Inventors: Son Minh PHAM, Jayakanth KANKANALA, Pradeep S. JADHAVAR, Baban Mohan MULIK, Farha KHAN, Sreekanth A. RAMACHANDRAN
  • Heterocyclic compounds as BET inhibitors
    Patent number: 11584756
    Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: February 21, 2023
    Assignee: NUVATION BIO INC.
    Inventors: Son Minh Pham, Sarvajit Chakravarty, Jayakanth Kankanala, Jiyun Chen, Chris P. Miller, Jeremy D. Pettigrew, Anjan Kumar Nayak, Anup Barde